A therapeutic compress assembly, system, and method for treating an area of a user is disclosed herein. The therapeutic compress assembly includes an elastic fabric compress and an absorbent pad. The elastic fabric compress is stretchable in a length direction and a width direction. The absorbent pad is coupled to a first side of the elastic fabric compress. The absorbent pad may be impregnated with a medication or an oil. In use, the therapeutic compress assembly is applied to the area of the user.

The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spasms, and pain and/or spasticity in multiple sclerosis.

Methods and formulations are provided for the treatment and prevention of portal hypertension.

The present invention relates to transdermal drug delivery system of pharmaceutical compositions, which have a satisfactory in-vitro performance and good bioavailability. In particular, the transdermal pharmaceutical composition of clobazam in the present invention includes a micro-emulsion in liquid or semi solid form, in a dosage form adapted for transdermal delivery (e.g., transdermal patch) for treatment of certain types of epilepsy and anxiety for continues application.

Compositions and methods for reducing the symptoms of skin conditions associated with the nail and surrounding tissue are provided. A medicated pad for cleaning and treating the nail and surrounding tissue is described, wherein said pad is saturated with a therapeutic composition comprising certain botanicals, an antimicrobial agent, a surfactant, and a moisturizing agent. The skin and nail conditions can include fungal infections of the nails. Kits for treating fungal infections of the nails are likewise described. Optionally, the kit may include a hydrating composition which includes shea butter, aloe, vitamins, arnica, emu oil, urea, and Vitamins C, A, E, and D. A bandage comprising a therapeutic pad instilled with an antifungal agent is also provided.

There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

Anhydrous hydrocolloid matrices contain one or more encapsulated therapeutic agents, including an acne agent and/or skin conditioning agent. The anhydrous hydrocolloid matrices are used as acne treatment dressings alone or in a laminate with a water-impermeable or semi-water impermeable backing and a release liner. The anhydrous hydrocolloid matrices are made using a premix of viscosity modifiers and hydrocarbon emollients and the one or more therapeutic agents, which are mixed via high shear mixing to form the premix. The resulting anhydrous hydrocolloid matrices include the one or more therapeutic agents which are encapsulated and homogeneously distributed therein.

Medaide is the only product of its kind that provides a band-aid strategically developed with a medicine carrier reservoir that can be easily puncture to release medication onto an affected skin site. This unprecedented product is uniquely designed with a durable adhesive skin color semi-transparent band-aid to complement diverse users and comes individually packed for easy transport and to preserve the sanitization of each covering.

A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.

The present invention concerns a transdermal therapeutic system, comprising a backing layer, which is not permeable for the active ingredient, and a matrix layer on one side of the backing layer, wherein the matrix layer contains at least one pressure sensitive adhesive and ketamine or a pharmaceutically acceptable salt or solvate thereof, wherein the at least one pressure sensitive adhesive has free hydroxyl groups, as well as its use as medicament, in particular for the treatment of depression and pain.